● GSK opens new state-of-the-art pharmaceutical manufacturing facilities worth $130m in Singapore. Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

葛蘭素史克投資1.3億新元在新加坡創(chuàng)建了進(jìn)的制藥生產(chǎn)設(shè)施。連續(xù)生產(chǎn)設(shè)施的建設(shè)和生產(chǎn)能力的擴(kuò)大將加速新的突破性藥品的供應(yīng)。

● One of the new continuous manufacturing facilities is part of Jurong's R&D Pilot Plant and will strengthen the site's capability in drug manufacture by allowing faster production of APIs (Active Pharmaceutical Ingredients) for clinical trials. The first New Chemical Entity (NCE) to be developed at the new facility will be Daprodustat, a new oral treatment for anaemia associated with chronic kidney disease. The new manufacturing process is expected to reduce production time of Daprodustat, enabling faster access to this medicine for patients globally.

其中一個新的連續(xù)生產(chǎn)設(shè)施是研發(fā)中試工廠，該中試工廠將加快原料藥API（活性藥物）生產(chǎn)能力來用于臨床試驗(yàn)。在新設(shè)施開發(fā)的個藥物將是Daprodustat（達(dá)布羅達(dá)特），一種新的口服治療與慢性腎病相關(guān)的貧血的藥物。新的制造工藝預(yù)計將縮短達(dá)布羅達(dá)特的生產(chǎn)時間，從而加快為患者提供這種藥物的速度。

● The expansion of the production building which makes APIs for HIV medicines will strengthen GSK's capability to produce Dolutegravir, a key GSK asset for HIV treatment. The investment has enabled the renewal of critical infrastructure in the production building and has allowed GSK to test and develop digital technologies in the manufacturing process to drive productivity improvement.

現(xiàn)有廠房的擴(kuò)建將擴(kuò)大生產(chǎn)制造DoluteGravir的能力， DoluteGravir是GSK的關(guān)鍵資產(chǎn)，用于HIV治療。投資使關(guān)鍵生產(chǎn)車間的基礎(chǔ)設(shè)施得到進(jìn)一步提升，并允許GSK測試和開發(fā)制造過程更加數(shù)字化以推動和提高生產(chǎn)力。

● The investment demonstrates GSK's commitment to Singapore as a key manufacturing and supply site for GSK's global pharmaceutical business and a testbed for advanced manufacturing technology. The investment behind the new facilities is part of the GSK-EDB 10-year Singapore Manufacturing Roadmap.

這筆投資表明，GSK致力于將新加坡打造成GSK制藥業(yè)務(wù)的關(guān)鍵生產(chǎn)、供應(yīng)基地以及試驗(yàn)中心。投資新工廠是GSK-EDB 十年新加坡制造藍(lán)圖中的一部分。

● Regis Simard, President Pharmaceuticals Supply Chain, GSK said, "As one of the most innovative cities in the world, Singapore is home to an ecosystem of companies and organisations that are creating and exporting innovative solutions. Innovation is at the heart of GSK, we are glad to invest in scientific and technical excellence in Singapore to develop and launch the next generation of products which meet the needs of patients, payers and consumers."

GSK制藥供應(yīng)鏈總裁雷吉斯·西馬爾說： “作為一個在世界上有創(chuàng)新精神的城市，新加坡有著良好的生態(tài)系統(tǒng)，是出口創(chuàng)新產(chǎn)品的公司和機(jī)構(gòu)的發(fā)源地。創(chuàng)新是GSK的核心，我們很高興在新加坡投資來發(fā)展和推出下一代新產(chǎn)品，滿足患者和消費(fèi)者。”

● Lim Hock Heng, Vice President & Site Director, Pharmaceuticals Supply Chain Singapore, GSK said, "Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector. Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines."

Lim Hock Heng，GSK新加坡藥品供應(yīng)副總裁兼地方總監(jiān)說，“先進(jìn)的制造系統(tǒng)是使葛蘭素史克保持在制藥行業(yè)的地位的關(guān)鍵。對數(shù)字制造業(yè)務(wù)和流程的進(jìn)一步投資將允許GSK確保藥品的生產(chǎn)效率和高品質(zhì)。

● Chng Kai Fong, Managing Director, EDB said, "Over the years, GSK has continually partnered with Singapore to develop advanced manufacturing technologies, such as continuous manufacturing and digital manufacturing. They have also been a strong partner in training our local talent. These efforts have supported the growth of the industry as a whole and in turn has created diverse and attractive job opportunities for Singapore."

EDB董事總經(jīng)理Chng Kai-fong說：“多年來，GSK不斷與新加坡合作，發(fā)展先*進(jìn)制造業(yè)技術(shù)，如連續(xù)制造和數(shù)字制造。他們在培訓(xùn)本地人才方面也是一個強(qiáng)有力的合作伙伴。這些努力支持了整個行業(yè)的發(fā)展，從而創(chuàng)造了新加坡的就業(yè)機(jī)會多樣化和吸引力。”

● About GSK-EDB 10-year Singapore Manufacturing Roadmap：In 2012, GSK and Singapore's Economic Development Board (EDB) jointly explored strategic investment options for GSK in Singapore that would be beneficial for both parties as part of their long-standing collaborative relationship. This led to the formation of a GSK-EDB 10-year Singapore Manufacturing Roadmap that aims to guide the investment decisions and developmental work to ensure manufacturing remains a competitive edge for both GSK and Singapore. This announcement is one of the collaborative areas in this 10-year roadmap.

關(guān)于GSK-EDB 十年新加坡制造藍(lán)圖：2012年，GSK與新加坡經(jīng)濟(jì)發(fā)展委員會（EDB）聯(lián)合，把探索新加坡GSK的戰(zhàn)略投資選擇作為對雙方都有利的長期合作的一部分。這就形成了GSK-EDB十年新加坡制造藍(lán)圖。旨在指導(dǎo)投資決策和開發(fā)工作，以確保GSK和新加坡在連續(xù)制造業(yè)上的競爭優(yōu)勢。

● About Continuous manufacturing：

Continuous manufacturing requires far fewer manual interventions than the traditional 'batch production' in which each stage of the production process takes place sequentially. It enables production to be quicker and at good quality standards. The flexible nature of the production process means that the volume of API produced can be adapted according to demand. There are also a number of environmental benefits from this technique, which will help to reduce the site's carbon footprint.

關(guān)于連續(xù)制造：連續(xù)制造所需的人工干預(yù)遠(yuǎn)遠(yuǎn)少于傳統(tǒng)的“批量生產(chǎn)”，生產(chǎn)的每個階段過程按順序進(jìn)行。它可以提高生產(chǎn)速度和產(chǎn)品質(zhì)量，且生產(chǎn)過程更加靈活。生產(chǎn)過程的靈活性意味著生產(chǎn)的原料藥的量可以根據(jù)需要進(jìn)行調(diào)整。有此外，這項(xiàng)技術(shù)還帶來了許多環(huán)境效益，這將有助于減少當(dāng)?shù)氐奶寂欧拧?/span>

● About GSK : GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

關(guān)于葛蘭素史克: GSK是一家以科學(xué)為主導(dǎo)的醫(yī)療保健公司，其特殊目的是：幫助人們做得更多，感覺更好，活得更長。

● About GSK's Jurong Site, Singapore：GSK's Jurong site was opened in 1982. The site, which now sits on a nine-hectare site, has evolved from bulk manufacture of established products in the early days to becoming a leading New Product Introductions (NPI) site within the GSK pharma supply chain.  It is focused on the development of late phase New Chemical Entities (NCEs) and delivering higher value products such as very active compounds in small batch sizes. The site currently has an R&D Pilot Plant where NCEs are developed and scaled up, and three production buildings making 13 Active Pharmaceutical Ingredients for a range of medicines prescribed for the treatment of respiratory, oncology, allergy, anti-viral and neurological conditions. There are about 490 employees working at the Jurong site.

關(guān)于GSK新加坡Jurong：葛蘭素史克在新加坡的Jurong設(shè)施于1982年開業(yè)，該基地現(xiàn)有面積9公頃。從早期的批量生產(chǎn)而發(fā)展成為GSK制藥供應(yīng)鏈內(nèi)的新產(chǎn)品導(dǎo)入（NPI）基地。目前已逐步發(fā)展建立了新的化學(xué)制造實(shí)體（NCE），并提供更高價值的產(chǎn)品，例如作為小批量的活性化合物。該地區(qū)目前擁有一個研發(fā)中試工廠，用于NCES的開發(fā)和放大。以及三個生產(chǎn)車間，生產(chǎn)的13種活性藥物成分用于治療呼吸、腫瘤學(xué)、過敏、抗病毒和神經(jīng)疾病。Jurong廠區(qū)現(xiàn)有490名員工。